首页> 美国卫生研究院文献>Oncotarget >MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway
【2h】

MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway

机译:MiR-204通过靶向SIRT1 / p53途径增强阿霉素治疗的前列腺癌细胞中的线粒体凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Chemotherapy is important for adjuvant treatment of prostate cancer. However, some cancer cells exhibited low sensitivity to chemotherapeutic agents. We are supposed to sensitize these prostate cancer cells to chemotherapeutic agents such as doxorubicin. Previous reports have suggested that microRNAs (miRNAs) regulate chemosensitivity in various cancers. In the present study, we observed that expression level of miR-204 was decreased in prostate cancer cell lines and patients’ tumors. Furthermore, we found that restore of miR-204 dramatically enhanced the cytotoxicity of doxorubicin (DOX) against prostate cancer cell lines C4-2 and LNCaP carrying wild type (WT) p53. Mechanically, miR-204 in prostate cancer cells targets SIRT1 which is a histone deacetylase, and thus decreasing deacetylation of p53. As the results, acetylated p53 induced by DOX upregulates the expression of Noxa and Puma followed by induction of mitochondrial apoptosis. These data demonstrate that restore of miR-204 in prostate cancer cells enhances the mitochondrial apoptosis induced by doxorubicin by targeting the SIRT1/p53 pathway.
机译:化学疗法对于前列腺癌的辅助治疗很重要。然而,一些癌细胞对化学治疗剂表现出低敏感性。我们应该使这些前列腺癌细胞对化学治疗剂(例如阿霉素)敏感。先前的报告表明,microRNA(miRNA)调节各种癌症的化学敏感性。在本研究中,我们观察到miR-204在前列腺癌细胞系和患者肿瘤中的表达水平降低。此外,我们发现miR-204的还原显着增强了阿霉素(DOX)对带有野生型(WT)p53的前列腺癌细胞系C4-2和LNCaP的细胞毒性。在机械上,前列腺癌细胞中的miR-204靶向作为组蛋白脱乙酰基酶的SIRT1,从而降低了p53的脱乙酰基。结果,DOX诱导的乙酰化p53上调了Noxa和Puma的表达,随后诱导了线粒体凋亡。这些数据表明,通过靶向SIRT1 / p53途径,前列腺癌细胞中miR-204的还原增强了由阿霉素诱导的线粒体凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号